ARDELYX, INC. Operating Expenses
ARDELYX, INC. (ARDX) reported Operating Expenses of $22.98 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2020-05-07
- ARDELYX, INC. operating expenses for the quarter ending 2020-03-31 was $22.98M, a 9.87% decline year-over-year.
- ARDELYX, INC. operating expenses for the quarter ending 2019-12-31 was $21.10M, a 23.17% decline year-over-year.
- ARDELYX, INC. operating expenses for the quarter ending 2019-09-30 was $24.50M, a 2.51% increase year-over-year.
- ARDELYX, INC. operating expenses for the quarter ending 2019-06-30 was $24.85M, a 12.00% increase year-over-year.
- ARDELYX, INC. operating expenses for fiscal 2019 was $95.94M, a 3.07% increase from fiscal 2018.
- ARDELYX, INC. operating expenses for fiscal 2018 was $93.09M, a 5.70% decline from fiscal 2017.
- ARDELYX, INC. operating expenses for fiscal 2017 was $98.72M, a 12.56% decline from fiscal 2016.
- ARDELYX, INC. operating expenses for fiscal 2016 was $112.89M, a 111.35% increase from fiscal 2015.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2020-03-31 | $22.98M 10-Q · filed 2020-05-07 | $44.08M derived: sum of 2 quarters · filed 2020-05-07 | $68.58M derived: sum of 3 quarters · filed 2020-05-07 | $93.43M derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-12-31 | $21.10M 10-K · filed 2020-03-06 | $45.60M derived: sum of 2 quarters · filed 2020-03-06 | $70.45M derived: sum of 3 quarters · filed 2020-03-06 | $95.94M 10-K · filed 2020-03-06 |
| 2019-09-30 | $24.50M 10-K · filed 2020-03-06 | $49.35M derived: sum of 2 quarters · filed 2020-03-06 | $74.85M 10-Q · filed 2019-11-06 | $102.31M derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-06-30 | $24.85M 10-K · filed 2020-03-06 | $50.34M 10-Q · filed 2019-08-09 | $77.81M derived: sum of 3 quarters · filed 2020-05-07 | $101.71M derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-03-31 | $25.50M 10-Q · filed 2020-05-07 | $52.96M derived: sum of 2 quarters · filed 2020-05-07 | $76.86M derived: sum of 3 quarters · filed 2020-05-07 | $99.05M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $27.46M 10-K · filed 2020-03-06 | $51.36M derived: sum of 2 quarters · filed 2020-03-06 | $73.55M derived: sum of 3 quarters · filed 2020-03-06 | $93.09M 10-K · filed 2020-03-06 |
| 2018-09-30 | $23.90M 10-K · filed 2020-03-06 | $46.09M derived: sum of 2 quarters · filed 2020-03-06 | $65.63M 10-Q · filed 2019-11-06 | $88.27M derived: sum of 4 quarters · filed 2020-03-06 |
| 2018-06-30 | $22.18M 10-K · filed 2020-03-06 | $41.73M 10-Q · filed 2019-08-09 | $64.36M derived: sum of 3 quarters · filed 2020-03-06 | $85.59M derived: sum of 4 quarters · filed 2020-03-06 |
| 2018-03-31 | $19.54M 10-K · filed 2020-03-06 | $42.18M derived: sum of 2 quarters · filed 2020-03-06 | $63.40M derived: sum of 3 quarters · filed 2020-03-06 | $89.82M derived: sum of 4 quarters · filed 2020-03-06 |
| 2017-12-31 | $22.64M 10-K · filed 2019-03-06 | $43.86M derived: sum of 2 quarters · filed 2019-03-06 | $70.28M derived: sum of 3 quarters · filed 2019-03-06 | $98.72M 10-K · filed 2020-03-06 |
| 2017-09-30 | $21.23M 10-K · filed 2019-03-06 | $47.64M derived: sum of 2 quarters · filed 2019-03-06 | $76.08M 10-Q · filed 2018-11-07 | $107.55M derived: sum of 4 quarters · filed 2019-03-06 |
| 2017-06-30 | $26.42M 10-K · filed 2019-03-06 | $54.85M 10-Q · filed 2018-08-07 | $86.33M derived: sum of 3 quarters · filed 2019-03-06 | $115.53M derived: sum of 4 quarters · filed 2019-03-06 |
| 2017-03-31 | $28.43M 10-K · filed 2019-03-06 | $59.91M derived: sum of 2 quarters · filed 2019-03-06 | $89.11M derived: sum of 3 quarters · filed 2019-03-06 | $117.80M derived: sum of 4 quarters · filed 2019-03-06 |
| 2016-12-31 | $31.48M 10-K · filed 2018-03-14 | $60.68M derived: sum of 2 quarters · filed 2018-03-14 | $89.37M derived: sum of 3 quarters · filed 2018-03-14 | $112.89M 10-K · filed 2019-03-06 |
| 2016-09-30 | $29.20M 10-K · filed 2018-03-14 | $57.89M derived: sum of 2 quarters · filed 2018-03-14 | $81.42M 10-Q · filed 2017-11-07 | $98.30M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-06-30 | $28.69M 10-K · filed 2018-03-14 | $52.22M 10-Q · filed 2017-08-09 | $69.09M derived: sum of 3 quarters · filed 2018-03-14 | $87.17M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-03-31 | $23.53M 10-K · filed 2018-03-14 | $40.41M derived: sum of 2 quarters · filed 2018-03-14 | $58.48M derived: sum of 3 quarters · filed 2018-03-14 | $67.57M derived: sum of 4 quarters · filed 2018-03-14 |
| 2015-12-31 | $16.88M 10-K · filed 2017-02-17 | $34.95M derived: sum of 2 quarters · filed 2017-02-17 | $44.04M derived: sum of 3 quarters · filed 2017-02-17 | $53.41M 10-K · filed 2018-03-14 |
| 2015-09-30 | $18.08M 10-K · filed 2017-02-17 | $27.17M derived: sum of 2 quarters · filed 2017-02-17 | $36.54M 10-Q · filed 2016-11-07 | $46.81M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-06-30 | $9.09M 10-K · filed 2017-02-17 | $18.46M 10-Q · filed 2016-08-08 | $28.73M derived: sum of 3 quarters · filed 2017-02-17 | $36.25M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-03-31 | $9.37M 10-K · filed 2017-02-17 | $19.64M derived: sum of 2 quarters · filed 2017-02-17 | $27.16M derived: sum of 3 quarters · filed 2017-02-17 | $33.55M derived: sum of 4 quarters · filed 2017-02-17 |
| 2014-12-31 | $10.27M 10-K · filed 2016-03-04 | $17.79M derived: sum of 2 quarters · filed 2016-03-04 | $24.17M derived: sum of 3 quarters · filed 2016-03-04 | $33.19M 10-K · filed 2017-02-17 |
| 2014-09-30 | $7.52M 10-K · filed 2016-03-04 | $13.90M derived: sum of 2 quarters · filed 2016-03-04 | $22.91M 10-Q · filed 2015-11-12 | $32.12M derived: sum of 4 quarters · filed 2016-03-04 |
| 2014-06-30 | $6.39M 10-K · filed 2016-03-04 | $15.40M 10-Q · filed 2015-08-12 | $24.61M derived: sum of 3 quarters · filed 2016-03-04 | $32.09M derived: sum of 4 quarters · filed 2016-03-04 |
| 2014-03-31 | $9.01M 10-K · filed 2016-03-04 | $18.22M derived: sum of 2 quarters · filed 2016-03-04 | $25.70M derived: sum of 3 quarters · filed 2016-03-04 | $33.84M derived: sum of 4 quarters · filed 2016-03-04 |
| 2013-12-31 | $9.21M 10-K · filed 2015-03-05 | $16.68M derived: sum of 2 quarters · filed 2015-03-05 | $24.83M derived: sum of 3 quarters · filed 2015-03-05 | $31.79M 10-K · filed 2016-03-04 |
| 2013-09-30 | $7.48M 10-K · filed 2015-03-05 | $15.62M derived: sum of 2 quarters · filed 2015-03-05 | $22.59M 10-Q · filed 2014-11-07 | |
| 2013-06-30 | $8.14M 10-K · filed 2015-03-05 | $15.11M 10-Q · filed 2014-08-08 | ||
| 2013-03-31 | $6.97M 10-K · filed 2015-03-05 | |||
| 2012-12-31 | $14.21M 10-K · filed 2015-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |